Is this under-the-radar pharma stock the next GlaxoSmithKline plc?

This little-known pharma stock could be the next giant if it’s international expansion continues.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Beximco Pharmaceuticals (LSE: BXP) flies under the radar of most investors despite the company’s enormous potential. 

Operating out of Bangladesh, Beximco designs, manufactures and supplies generic versions of drugs that have come off patent. The company is extremely good at this. Between 2011 and the end of the company’s 2016 financial year, sales grew at an average rate of 25.3% per annum, and net profit expanded at an average annual rate of 23% over the same period. 

Despite this growth, investors have avoided Beximco for much of the past five years. Over the five years to the end of 2015, shares in the company fell by 40%, as the market seemingly gave up on Beximco. However, this year the market has regained confidence. Shares in Beximco have gained close to 100% year-to-date and there could be further gains to come. 

Further growth ahead

Beximco is one of the world’s fastest growing pharma companies and it’s also Bangladesh’s most successful business. This year it has become the first Bangladeshi firm to ship medicine to the United States, the first Bangladeshi company to receive approval for the sale of its products within Canada, and the first Bangladeshi company to enter the Gulf market. All of these approvals are a testament to its goal of providing high-quality treatments at affordable prices. The company produces more than 500 products in different dosage forms covering broad therapeutic categories with many more under development. 

The most exciting part of Beximco’s investment case is the company’s growth potential. For much of its life, it has been a domestic pharmaceutical company, producing treatments for its home market in Bangladesh. Back in 2014, just 6% of Beximco’s sales were to the export market. 

Today, management is concentrating on driving export growth. Since 2014 the company has been granted the rights to sell its products in Europe and the US, as well as other smaller regions. This export drive has supercharged the group’s growth. For the three months ended September 30, Beximco reported year-on-year revenue growth of 12%, pre-tax profit up 24%, and earnings per share up 22%.

However, despite this growth the shares are trading at an astonishingly low forward P/E of just 9.3. 

Under the radar 

Beximco seems to fly under the radar of most investors, which is why the shares trade at an attractive valuation. The pharmaceutical sector average P/E is 14.3, making Beximco one of the sector’s cheapest opportunities. 

Now the company is exporting outside of Bangladesh, this discount doesn’t make much sense. Indeed, if the group’s sales continue to grow at their current rate (and as the company starts to conquer the rest of the world there’s no reason why they can’t) Beximco could quickly become one of the world’s premier drug manufacturers taking on the likes of GlaxoSmithKline

Even though Beximco is a tiddler compared to Glaxo today, global expansion could quickly change that. 

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Rupert Hargreaves owns shares of GlaxoSmithKline. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Happy parents playing with little kids riding in box
Investing Articles

2 FTSE 250 dividend growth stocks I’m considering for passive income

Paul Summers thinks the best dividend stocks to buy are those that consistently return more money to investors every year.

Read more »

Investing Articles

The Compass Group share price looks ready for growth after positive 2024 results

The Compass Group share price is up 4% today following positive full-year results. Our writer considers its prospects in 2025…

Read more »

Young mixed-race couple sat on the beach looking out over the sea
Investing Articles

How I plan to build an £86k yearly second income in the stock market

Is it realistic to aim for a substantial future second income by investing in high-quality shares? This writer firmly believes…

Read more »

Investing Articles

Here’s the Vodafone share price forecast up to 2027

Can anything stop the Vodafone share price slide? It's still early days for the company's turnaround plan, so we might…

Read more »

Investing Articles

Down 37%, here’s one of my favourite FTSE 100 bargain shares to consider

This FTSE 100 retailer's shares have collapsed in 2024. Despite tough trading conditions, is now the time to consider buying…

Read more »

Investing Articles

Which do I like best today, Nvidia or Tesla stock?

EV maker Tesla stock is on the up, while Nvidia growth is softening a bit. But they're both in the…

Read more »

Investing Articles

After jumping 15%, my favourite FTSE 250 stock looks set for the premier league

Games Workshop stock recently reached an all-time high, placing it within touching distance of promotion from the FTSE 250.

Read more »

Surprised Black girl holding teddy bear toy on Christmas
Investing Articles

1 top growth stock on my Christmas buy list!

Ben McPoland reveals one top-notch growth stock down 29% that he plans to stuff into his portfolio in time for…

Read more »